Aktis Oncology (NASDAQ: AKTS) CSO discloses stock and option holdings

Rhea-AI Filing Summary

Aktis Oncology, Inc. filed an initial Form 3 showing that its Chief Scientific Officer, Paul L. Feldman, beneficially owns 144,568 shares of common stock directly as of January 8, 2026.

He also holds several stock options to buy common stock: one option for 65,713 shares at an exercise price of $1.91 per share expiring on April 14, 2031, which has vested in full; an option for 119,248 shares at $3.66 per share expiring on November 15, 2032 that vests monthly after 25% vested on November 1, 2023; an option for 90,684 shares at $9.33 per share expiring on October 10, 2034 with similar monthly vesting after 25% vested on October 9, 2025; and an option for 131,246 shares at $18 per share expiring on January 7, 2036, with 25% scheduled to vest on January 8, 2027 and the remainder in monthly installments, all subject to his continuous service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Feldman Paul L

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	144,568	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	04/14/2031	Common Stock	65,713	$1.91	D
Stock Option (Right to Buy)	(2)	11/15/2032	Common Stock	119,248	$3.66	D
Stock Option (Right to Buy)	(3)	10/10/2034	Common Stock	90,684	$9.33	D
Stock Option (Right to Buy)	(4)	01/07/2036	Common Stock	131,246	$18	D

Explanation of Responses:

1. These options have vested in full.

2. 25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

3. 25% of the original number of shares subject to the option vested on October 9, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

4. 25% of the original number of shares subject to the option shall vest on January 8, 2027, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Paul L. Feldman	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Aktis Oncology (AKTS) Form 3 filing report?

The Form 3 reports that Aktis Oncology Chief Scientific Officer Paul L. Feldman is a beneficial owner of company securities, detailing his holdings of common stock and multiple stock options as of January 8, 2026.

How many Aktis Oncology (AKTS) common shares does Paul L. Feldman beneficially own?

Paul L. Feldman beneficially owns 144,568 shares of Aktis Oncology common stock, held directly.

What stock options are reported for the Aktis Oncology (AKTS) Chief Scientific Officer?

The filing lists four stock options to buy Aktis Oncology common stock: 65,713 shares at $1.91 per share expiring April 14, 2031; 119,248 shares at $3.66 per share expiring November 15, 2032; 90,684 shares at $9.33 per share expiring October 10, 2034; and 131,246 shares at $18 per share expiring January 7, 2036, all held directly.

How do the vesting schedules work for Paul L. Feldman’s Aktis Oncology stock options?

One option for 65,713 shares has vested in full. For the other three grants, 25% of the original shares vest on a specified initial vesting date and the remaining 75% vest in 1/48th monthly installments thereafter, subject to Paul L. Feldman’s continuous service through each vesting date.

When do the Aktis Oncology (AKTS) stock options reported in the Form 3 expire?

The reported options expire on April 14, 2031, November 15, 2032, October 10, 2034, and January 7, 2036, respectively, for the four separate stock option grants.

Does this Aktis Oncology (AKTS) Form 3 show any stock sales by Paul L. Feldman?

No transactions such as purchases or sales are listed; the Form 3 presents holdings of common stock and stock options as of January 8, 2026.